Table 5.
AADs reported with positive and negative effects for the treatment of PVCs and idiopathic VT306
| β-Blockers | CCB | Ic | Sotalol | Amiodarone | Ranolazine | |
|---|---|---|---|---|---|---|
| Idiopathic RVOT PVCs/VT no SHD |
++ | ++ | ++ | + | − | ? |
| Idiopathic fascicular PVCs/VT no SHD |
+ | ++ | + | ? | − | ? |
| Idiopathic non-RVOT/fascicular PVCs/VT No SHD |
++ | ++ | + a | + | − | ? |
| PVCs/VT PVC/VT-induced cardiomyopathy |
++ | − | + b | ? | + | ? |
| PVCs SHD |
++ | − | − | + | + | + c |
++, preferred positive AAD effects; +, conditional use and/or less established positive effect; −, to be avoided; ?, not enough data.
Abbreviations: AAD, anti-arrhythmic drug; CCB, calcium channel blockers; PVC, premature ventricular contraction; RVOT, right ventricular outflow tract; SHD, structural heart disease; VT, ventricular tachycardia.
aNot to be used if unmasked SHD or malignant short-coupled PVCs are suspected.
bOnly if no heart failure or severe ventricular dysfunction are present (risk of myocardial contractility depression).
cIf ischaemic heart disease is present.